Search for a trial | Research with human participants

1 results

A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-512244-36-00 check the CTIS register for the current data. The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and…